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Acute hepatitis E virus (HEV) infection is a leading cause of acute liver failure (ALF) in many developing countries, yet rarely identi-
fied in Western countries. Given that antibody testing for HEV infection is not routinely obtained, we hypothesized that HEV-
related ALFmight be present and unrecognized in North American ALF patients. Serum samples of 681 adults enrolled in the U.S.
Acute Liver Failure Study Group were tested for anti-HEV immunoglobulin (Ig) M and anti-HEV IgG levels. Subjects with a
detectable anti-HEV IgM also underwent testing for HEV RNA.Mean patient age was 41.8 years, 32.9% were male, and ALF eti-
ologies included acetaminophen (APAP) hepatotoxicity (29%), indeterminate ALF (23%), idiosyncratic drug-induced liver injury
DILI (22%), acute hepatitis B virus infection (12%), autoimmune hepatitis (12%), and pregnancy-related ALF (2%). Three men
ages 36, 39, and 70 demonstrated repeatedly detectable anti-HEV IgM, but all were HEV-RNA negative and had other putative
diagnoses. The latter 2 subjects died within 3 and 11 days of enrollment whereas the 36-year-old underwent emergency liver trans-
plantation on study day 2. At admission, 294 (43.4%) of the ALF patients were anti-HEV IgG positive with the seroprevalence
being highest in those from theMidwest (50%) and lowest in those from the Southeast (28%). Anti-HEV IgG1 subjects were signif-
icantly older, less likely to have APAP overdose, and had a lower overall 3-week survival compared to anti-HEV IgG- subjects (63%
vs. 70%; P 5 0.018). Conclusion:Acute HEV infection is very rare in adult Americans with ALF (i.e., 0.4%) and could not be impli-
cated in any indeterminate, autoimmune, or pregnancy-related ALF cases. Past exposure to HEV with detectable anti-HEV IgG
was significantly more common in the ALF patients compared to the general U.S. population. (HEPATOLOGY 2016;64:1870-1880)
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H
epatitis E virus (HEV) is an enterically
transmitted single-stranded RNA virus that
is a common cause of sporadic hepatitis in
India and other tropical countries.(1) The diagnosis of
acute HEV infection requires the detection of anti-
HEV immunoglobulin (Ig) M or HEV RNA in the
serum or stool of an affected patient or the develop-
ment of anti-HEV IgG within 6-12 months in a
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patient who was previously seronegative.(1,2) However,
only 50%-66% of symptomatic patients with acute
HEV infection have detectable HEV RNA in the
blood.(1,2) In endemic areas, acute HEV is most com-
monly attributed to infection with HEV genotype 1 or
2 and has been associated with the development of
acute liver failure (ALF), particularly in pregnant
women.(3,4) Subjects with underlying chronic liver dis-
ease (CLD) may also develop acute-on-chronic liver
failure (ACLF) after acute HEV infection.(5,6)
Acute HEV infection is rarely encountered in most
developed countries unless someone has a history of
travel to an endemic area like Asia or Africa.(2,7,8)
However, as many as 20% of individuals in the general
U.S. population have detectable anti-HEV IgG indic-
ative of past exposure with no antecedent history of
hepatitis suggesting previous subclinical infection.(9)
Acute symptomatic HEV infection in developed
nations is believed to be a zoonosis wherein HEV
genotype 3 is transmitted to humans through con-
sumption of undercooked pork or wild game.(10)
Recent reports from the United Kingdom and Aus-
tralia suggest that acute sporadic HEV infection may
account for 5%-10% of presumed drug-induced liver
injury (DILI) cases.(11,12) The U.S. Drug-Induced
Liver Injury Network (DILIN) also demonstrated that
9 of 318 (3%) consecutive patients with suspected
DILI were actually likely attributed to acute HEV,
given that all were anti-HEV IgM positive and 4 had
detectable HEV RNA in their blood.(13)
The U.S. Acute Liver Failure Study Group
(ALFSG) is a consortium of academic medical centers
that has been studying the etiologies and outcomes of
adult patients with ALF for the past 18 years.(14) Eti-
ologies identified include acetaminophen (APAP)
hepatotoxicity (46%), idiosyncratic DILI (10%), auto-
immune hepatitis (7%), hepatitis B virus (HBV; 7%),
and various other etiologies. Despite extensive testing
for identifiable causes of ALF with highly sensitive
molecular diagnostic assays, imaging, and histological
analysis, roughly 10% of adult ALFSG patients have
no identifiable cause of ALF and remain
“indeterminate.” Previous studies in indeterminate
ALF patients looking for occult herpes simplex virus,
SEN virus, hepatitis B, and parvovirus infections have
been unrevealing.(15-17) In the current study, we tested
sera from a large cohort of adult patients to determine
the presence of previously unrecognized acute HEV
infection in indeterminate, autoimmune, HBV, DILI,
and pregnancy-related ALF. In addition, we examined
the seroprevalence of past HEV infection defined as
detectable anti-HEV IgG in consecutive patients. Our
final aim was to determine whether any subjects with
acute HEV infection or those who have undergone
liver transplantation (LT) have evidence of chronic
HEV infection in long-term follow-up serum samples.
Patients and Methods
ALFSG STUDY PROTOCOL
This consortium of academic medical centers,
funded by the National Institutes of Health (NIH),
has continued an ongoing prospective observational
study of consecutive ALF patients observed at their
centers since 1998.(14) The study group administrative
center is at the University of Texas Southwestern
Medical Center (Dallas, TX) with the data coordinat-
ing center at the Medical University of South Carolina
(Charleston, SC). Eligible patients have symptoms of
new-onset jaundice or hepatitis of less than 26 weeks
before admission and mental status changes with coa-
gulopathy defined as an international normalized ratio
(INR) >1.5 without known underlying CLD. In addi-
tion to baseline demographics and presenting features,
detailed information during the first 7 days of
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enrollment, including imaging, lab, and clinical data,
as well as outcome data, are obtained through 21 days
after admission. In addition, long-term clinical data
collected at 1 and 2 years after enrollment are available
in patients enrolled after 2000.(18) Blood samples are
also collected from participants at enrollment and for 7
consecutive days as well as at long-term follow-up
study visits. The study protocol was reviewed and
approved by the institutional review board of partici-
pating sites, and written informed consent was
obtained from the next of kin of eligible patients
because of their impaired mental status. The current
study protocol to analyze deidentified serum samples
and data was approved by the institutional review
boards at the University of Michigan (Ann Arbor, MI)
and at the NIH.
HEV TESTING
Day 1 sera (or the earliest day with available serum)
from ALF patients randomly selected from those
enrolled between 1998 and July 2011 had been stored
at -808 C before shipment for testing for anti-HEV
IgM and anti-HEV IgG. The anti-HEV IgM, anti-
HEV IgG, and HEV-RNA testing were completed in
the Clinical Laboratory Improvement Amendments-
certified research lab of Dr. Robert Purcell at the
National Institute of Allergy and Infectious Diseases
(NIAID). A modification of the enzyme-linked
immunosorbent assay (ELISA) assay described was
used to test all samples for anti-HEV IgG using 10 uL
of serum in duplicate, and positive controls were run
on each plate.(19) In addition, anti-HEV IgM was
detected using a class-capture enzyme-linked immuno-
sorbent assay (ELISA) assay using 10 uL of serum in
duplicate.(20,21) All samples that were positive for anti-
HEV IgM using the ELISA assay were also tested
using the Wantai HEV IgM Elisa (Wantai, Beijing,
China), which has superior sensitivity in some stud-
ies.(22,23) An independent serum sample was also
tested for HEV RNA, using consensus primers, from
a 140-uL sample of serum by real-time polymerase
chain reaction (PCR).(24) The lower limit of detection
of the HEV-RNA test was 50 genome equivalents
(GE)/reaction or 3.3 log10 GE/mL. For patients with
an indeterminate anti-HEV IgG test results (i.e.,
within 10% of the cutoff), a serum sample was retested
using a confirmatory IgG blocking test, but we could
not confirm the presence of detectable anti-HEV IgG.
Of note, all 18 patients with indeterminate anti-HEV
IgG test results were anti-HEV IgM negative. Avail-
able long-term follow-up serum samples from patients
with an initial anti-HEV IgG-positive sample under-
went testing for anti-HEV IgM and quantitative anti-
HEV IgG titers.
Acute HEV infection was defined as a patient with
anti-HEV IgM1 on repeated testing with or without
HEV-RNA1 or a patient with repeatedly positive HEV
RNA, independent of anti-HEV IgM and IgG levels.
Past exposure to HEV infection was defined as a patient
with anti-HEV IgG1 alone (i.e., anti-HEV IgM (2)).
STATISTICAL ANALYSES
Statistical analyses were performed using SAS software
(version 9.2; SAS Institute Inc., Cary, NC). A popula-
tion of 678 subjects with definitive anti-HEV IgG test
results was analyzed using descriptive statistics to charac-
terize demographics and other clinical variables describ-
ing illness severity, treatment, and outcomes. Differences
between the anti-HEV IgG-positive and anti-HEV
IgG-negative test result groups were tested using the
Student t test for continuous measures, the chi-square
test for categorical measures, and the Fisher’s exact test
for categorical measures with expected cell sizes less than
five. All tests were assessed at the 0.05 significance level.
Logistic regression analysis was used to determine
whether the probability of testing anti-HEV IgG-posi-
tive was affected by prespecified prognostic variables.
Results
ACUTE HEV INFECTION
Between January 1998 and July 2011, serum samples
from 699 eligible patients were available for testing of
anti-HEV IgM and anti-HEV IgG levels. In 18
patients, anti-HEV IgG test results were indetermi-
nate even on repeat testing, possibly attributed to IgG
levels below the detection limit of the assay or the pres-
ence of interfering substances. The etiology of ALF,
age, sex hepatic encephalopathy (HE) grade, and fre-
quency of blood transfusions before and after enroll-
ment was not significantly different from those with
interpretable results (data not shown), and all of these
patients were anti-HEV IgM negative. Therefore, for
this analysis, only the results of 681 patients with a
positive or negative value for anti-HEV IgM are
included (Fig. 1). Overall, only 3 of the 681 patients
(0.4%) tested persistently positive for anti-HEV IgM.
However, follow-up testing of eight independent
serum samples in these 3 patients failed to demonstrate
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any detectable HEV RNA. These 3 male Caucasian
patients were enrolled with ALF initially attributed to
alternative etiologies as summarized below.
CASE 1
A 71-year-old Caucasian male with hyperlipidemia
and atherosclerotic heart and carotid disease presented
to a Midwestern hospital in 2004 with a 6-week history
of malaise, fever, and progressive weakness with jaun-
dice. His initial biochemical findings included serum
alanine aminotransferase (ALT) 1,868 IU/L, aspartate
aminotransferase (AST) 2,724 IU/L, and bilirubin of
10.4 mg/dL. A transjugular liver biopsy showed lobular
necroinflammatory activity with necrotic hepatocytes
and predominance of plasma cells in the portal tracts
attributed to presumed atorvastatin hepatotoxicity (Fig.
2). After discharge, he was rehospitalized 10 days later
for altered mental status with a serum ALT of 128 U/L
and bilirubin of 2.5 mg/dL. Medications at presentation
included famotidine, questran, aspirin, a multivitamin,
and atorvastatin 10 mg per day that he had been on for
2 months. At study enrollment, he had normal vital
signs, grade 1 encephalopathy, mild leg edema, and
ascites. Labs at study enrollment included a white blood
cell count (WBC) of 6.4 3 10 3/mL, hemoglobin 8.9
g/dL, platelets 35 3 103/mL, serum creatinine of 3.3
mg/dL, and a pH of 7.23/21/70 on 60% oxygen. His
serum ALT was 62 U/L, AST 89 U/L, alkaline phos-
phatase (ALP) 152 U/L with a total bilirubin of 40.5
mg/dL and INR of 1.6. Testing for anti-HAV (hepati-
tis A virus) IgM, hepatitis B surface antigen (HBsAg),
hepatitis B core antigen (anti-HBc) IgM, and anti-
HCV (hepatitis C virus) were all negative, as was liver
imaging and a urine toxicology screen.
Despite supportive measures, he deteriorated with a
peak bilirubin of 45 mg/dL and required intubation
and hemodialysis. He died of cardiac arrest on study
day 11, and no autopsy was performed. His initial
study day 2 serum samples were strongly positive for
anti-HEV IgM and were confirmed with testing of
independent study day 2 and 3 serum samples. His ini-
tial anti-HEV IgG titer was also strongly positive, but
HEV RNA was repeatedly negative.
CASE 2
This 36-year-old Caucasian male presented with 4
days of nausea, vomiting, and abdominal pain to a
Northeastern hospital in 2006. The patient reported a
history of depression, migraines, and past spinal fusion
for which he had been receiving APAP-oxycodone for
the past month as well as losartan/hydrochlorothiazide,
esomeprazole, wellbutrin, and valium. At study day 1,
he had a blood pressure of 171/101 and grade IV ence-
phalopathy with hyper-reflexia and was intubated. His
WBC was 4.3 3 103/mL, hemoglobin 13.4 g/dL, and
platelets 112 3 10 3/mL and creatinine 5.6 mg/dL.
His serum AST was 1,858 U/L, ALT 1,866 U/L, and
ALP 103 U/L, with total bilirubin 12.8 mg/dL and
INR 5.3. At presentation, his serum APAP level was
not detected and urine toxicology screen was positive
for benzodiazepenes and opiates. Diagnostic studies,
including anti-HAV IgM, anti-HCV, HCV RNA by
PCR, and anti-HIV (human immunodeficiency virus),
as well as anti-nuclear antibody (ANA) and smooth-
muscle antibody (SmAb), were all negative. His initial
local HBsAg was positive, but anti-HBc IgM, hepati-
tis B e antigen (HBeAg), and HBV DNA were nega-
tive or not detected. No blood products had been given
before the day 1 serum sample.
The patient was intubated, had an intracranial pres-
sure monitor placed, and underwent emergency LT on
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FIG. 1. Overview of study population. Of the 699 ALFSG
patients with serum that were tested for anti-HEV IgM, 681
had interpretable anti-HEV IgM results. There were 3 subjects
who were repeatedly anti-HEV IgM1 and anti-HEV IgG1 as
well. Among the 678 anti-HEV IgM- subjects, there were 57%
who were anti-HEV IgG- and 43% anti-HEV IgG1. Abbrevia-
tion: AIH, autoimmune hepatitis.
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study day 2. His explant pathology showed submassive
zone 2 and 3 necrosis and there was severe cholestasis,
both intrahepatocytic and canalicular, with extensive
formation of ductular hepatocytes and a prominent
ductular reaction. HBV core and surface antigen
immunostains were negative. At a long-term follow-up
study visit 31 months after enrollment, he was doing
well and had normal liver biochemistries. He was not
receiving any antivirals for HBV and was only on
mycophenolate, amlodipine, and metoprolol. His ini-
tial study day 1 anti-HEV IgM was positive on first
testing, but repeat testing of study day 1 and additional
samples from study day 2 were negative. Testing of
study day 1 and 2 samples using the Wantai kit was
positive in 2 of 3 instances for anti-HEV IgM. Initial
anti-HEV IgG was strongly positive, but his month
31 serum sample was anti-HEV IgG negative.
Repeat testing of study day 1 stored serum at the
NIAID failed to demonstrate any detectable HBsAg,
anti-HBc, anti-HCV, or anti-HDV (hepatitis D virus)
using standard ELISA assays. In addition, HBV
DNA and HCV RNA were not detectable by PCR.
However, a study day 1 serum sample did have detect-
able serum cysteine-APAP adducts with a level of 1.73
nmoles/mL (normal, <1.0 nmole/mL). Therefore, the
initial clinical diagnosis of indeterminate ALF was
incorrect, and this patient’s clinical course was more
consistent with inadvertent APAP hepatotoxicity and
possible concomitant acute HEV infection.(21) How-
ever, the lack of persistent anti-HEV IgG during
follow-up makes the latter diagnosis less likely.
CASE 3
This 39-year-old Caucasian male presented with a
2-week history of nausea, malaise, and jaundice in
2008. The patient had a history of crack cocaine use
and depression. He was receiving no medications and
denied any recent travel. At study enrollment, he had a
temperature of 38.28C, blood pressure of 109/63, asci-
tes on exam, and was intubated with grade IV ence-
phalopathy and evidence of cerebral edema by head
computed tomography. His initial WBC was 11.5 3
103/mL, hemoglobin 12.9 g/dL, and platelets 106 3
103/mL with a serum creatinine of 2.1 mg/dL. His
initial serum AST was 257 U/L, ALT 295 U/L, ALP
95 UL, and total bilirubin 24.6 mg/dL with INR of
8.8. His serum APAP level was undetectable and anti-
HAV IgM, anti-HCV, and HCV RNA were all nega-
tive. However, his serum tested positive for HBsAg1
and anti-HBc IgM1, and plasma HBV-DNA titer
was 6,610 IU/mL. Local testing for HIV, anti-HDV,
ANA, and SmAb and HBeAg were not done. The
patient was treated with supportive care and placed on
lamivudine; he was not listed for LT because of active
substance abuse. He died on study day 3 of multiorgan
failure and an autopsy was not performed.
Initial anti-HEV IgG testing from study days 1
and 2 was strongly positive, as was study day 1 serum
for anti-HEV IgM. However, repeat testing of inde-
pendent day 1 and 2 samples were negative. Testing
of independent study day 1 and 2 samples using the
more sensitive Wantai kit showed that one of two was
anti-HEV IgM1 and the other sample was borderline
positive as well. Repeat testing of his study day 1
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FIG. 2. Representative liver histopathology from an acute HEV
patient. (A,B) A transjugular liver biopsy demonstrates bridging
and chicken-wire fibrosis as well as Mallory bodies on trichrome
stain suggestive of antecedent nonalcoholic steatohepatitis (mag-
nification, 3400). Photomicrograph provided by Dr. Lan Peng
of University of Texas Southwestern (Dallas, TX).
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serum for anti-HBc (IgM) was strongly positive with
a signal/noise ratio of 83 suggesting acute HBV infec-




Overall, 294 of the 678 patients (43.4%) without
acute HEV infection were anti-HEV IgG positive.
Individuals with detectable anti-HEV IgG were sig-
nificantly older and more likely to be non-Caucasian
(Table 1). In addition, they had a longer mean dura-
tion of symptoms before presentation and were signifi-
cantly more likely to have had a non-APAP etiology of
ALF with lower serum ALT levels. The anti-HEV
IgG seropositive patients were more likely to have
grade 3/4 encephalopathy at admission and to undergo
LT, and, not surprisingly, their overall survival at 3
weeks after enrollment was significantly lower (63% vs.
70%; P 5 0.018). The anti-HEV IgG1 patients were
also more likely to have received blood products both
before and after study enrollment. Assessment of the
year enrollment demonstrated that the proportion of
anti-HEV IgG1 cases significantly decreased over
time (P 5 0.0198, Cochran-Armitage test; Supporting
Fig. S1).
A multivariate logistic regression model was
constructed to identify independent predictors of anti-
HEV IgG1 serostatus (Table 2). Patients with non-
APAP etiologies, older individuals, recipients of a
blood product transfusion before enrollment, earlier
year of enrollment, and those with grade 3/4 encephal-
opathy were significantly more likely to be anti-HEV
IgG positive. The c-statistic for the model was 0.660.
TABLE 1. Presenting Features and Outcomes of ALF Patients




N 5 294 P Value
Age, years 40 1 14 44 1 15 0.001
% Male 32 33 0.72
% Caucasian 77 67 0.003
% African American 16 19
% Other 7 14
% Hispanic 12 9 0.332
BMI, kg/m2 28 1 7 28 2 7 0.988
Symptoms to enrollment (days) 15 1 19 19 1 21 0.009
Etiology of ALF
% Acetaminophen 35 22 0.0002
% Nonacetaminophen 65 78
Initial ALT, IU/mL 2,782 1 3,490 2,203 1 2,796 0.017
Initial ALP, IU/mL 175 1 132 179 1 141 0.715
Initial bilirubin, mg/dL 15 1 12 17 1 12 0.014
INR 3.8 1 2.7 3.7 1 3.5 0.727
Creatinine, mg/dL 2.1 1 1.9 2.0 1 1.6 0.741
% Grade 3/4 encephalopathy 42 55 0.0008
% Hemodialysis/CVVH 30 30 0.83
% Intubated 56 63 0.069
Outcomes at 3 weeks*
% Alive 71 63 0.018
% Died 29 37
% Transplanted at 3 weeks 29 35 0.086
% Transfusion pre-enrollment 40 56 <0.0001
% Transfusion postenrollment 67 78 0.001
Data presented as mean1 SD or %.
*Seven subjects were lost to follow-up with missing outcome data.
Abbreviations: BMI, body mass index; CVVH, continuous venovenous hemodialysis.




(95% CI) P Value
Non-APAP etiology 1.92 (1.34, 2.77) 0.0005
Grade 3/4 HE at admission 1.57 (1.12, 2.19) 0.0081
Blood transfusion prestudy 1.87 (1.34, 2.61) 0.0003
Age (per 10 years) 1.19 (1.07, 1.33) 0.0034
Year of enrollment 0.95 (0.90, 0.99) 0.0190
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SEROPREVALENCE OF ANTI-HEV
IgG IN ALF PATIENTS COMPARED
TO U.S. POPULATION CONTROLS
A previous study using the same assay demonstrated
that the seroprevalence of anti-HEV IgG in the United
States was, in part, related to subject age, sex, and geo-
graphical location.(7) The proportion of anti-HEV IgG-
positive patients in our cohort was significantly higher
than that reported in the general U.S. population of 18,
695 individuals (43.4% vs. 21.0%; P < 0.0001, chi-
square), but we were unable to control for differences in
participant age and sex. In our cohort, the region of the
country where the patient was enrolled was a strong corre-
late of anti-HEV IgG seropositivity, with subjects enrolled
in the Southeast being least likely to be anti-HEV IgG
positive compared to those from other regions (Fig. 3).
Among the 28 individual sites that contributed cases, the
highest seroprevalence for anti-HEV IgG was noted in
Nebraska (77%) and the lowest was reported in Alabama
(17%) and Arizona (0%). Analyses exploring seasonal or
longitudinal trends over timewith anti-HEV IgG serosta-
tus did not identify a relationship (data not shown).
PERSISTENCE OF ANTI-HEV IgG
LEVELS DURING FOLLOW-UP
Among the 294 anti-HEV IgG1 patients, long-
term follow-up serum samples were available for repeat
testing in 20 subjects at a median of 19.6 months after
initial enrollment. Six of the 20 patients had persis-
tently detectable anti-HEV IgG levels whereas 14 lost
their antibody over time (Fig. 4). Neither the initial
anti-HEV IgG titer nor use of blood products before
ALF enrollment were associated with persistence of
anti-HEV IgG levels over time (data not shown).
Discussion
Previous reports from the ALFSG have demon-
strated that a sizable proportion (11%) of adult Ameri-
cans with ALF are of indeterminate etiology.(14) Many
of these patients present with a viral prodrome of mal-
aise, fever, and fatigue over several weeks, yet testing
for occult viral infections has been repeatedly nega-
tive.(15-17) However, as many as 18% of these indeter-
minate ALF patients have detectable serum APAP-
protein adducts, which indicate that they likely were
misclassified and could have potentially benefited from
N-acetylcysteine therapy.(25) Even if a small proportion
of the indeterminate ALF patients had undiagnosed
acute HEV infection, this could have important epide-
miological implications as well as clinical implications
for the patients undergoing LT. It is also important to
determine whether some DILI-related ALF cases are
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FIG. 3. Seroprevalence of anti-HEV IgG1 ALF patients by site
location. There were 28 sites in the U.S. ALFSG who contrib-
uted samples to this study over a 13-year period. When the fre-
quency of anti-HEV IgG1 samples was analyzed by geographical
location, patients enrolled in the eight Southeastern sites had a
statistically significantly lower seroprevalence rate compared to
the other regions of the United States (28% vs. 48%; P < 0.001).
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FIG. 4. Initial and follow-up anti-HEV IgG levels in ALF
patients over time. (A) There were 6 patients with a positive anti-
HEV IgG baseline serum sample that remained positive at their
month 12 and or month 24 study visit. (B) There were 14 patients
who also had a positive anti-HEV IgG baseline serum sample that
became negative with a level of <1.0 at their month 12 or 24
study visit. Abbreviations: Avg, average; LTFU, long-term follow-
up; NEG, negative; POS, positive; S/C, sample over cutoff.
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actually attributed to acute HEV infection given that
DILI is a clinical diagnosis of exclusion and previous
studies have demonstrated a significant frequency of
acute HEV infection in these patients.(11-13) Identifi-
cation of HEV infection in pregnant women with
ALF is also of interest given that previous studies have
suggested that acute HEV infection may be more
severe in pregnant patients and associated with sub-
stantial maternal and fetal mortality.(3,4) Testing for
occult HEV infection with known or suspected fulmi-
nant HBV infection is of interest given that ACLF has
been previously reported in patients with chronic HBV
and HEV superinfection.(5,6) Finally, we tested
patients with presumed autoimmune ALF because this
diagnosis is notoriously difficult to establish and
empiric use of steroids could be detrimental if the
patients actually had unsuspected acute HEV
infection.(26)
In the current study, only 3 of the 681 (0.4%) ALF
patients tested had detectable anti-HEV IgM and
none of these had detectable HEV RNA despite the
acute nature of their presentations. These data indicate
that previously unsuspected acute HEV infection is
exceedingly uncommon in American adults presenting
with ALF. The 3 patients who tested anti-HEV IgM
positive were all non-Hispanic, Caucasian men, and 2
of the cases originated from a single center in the
Northeast, but were separated in time by 2 years. In
the United States, sporadic cases of severe acute HEV
infection have been reported by the DILIN as well as
by the Centers for Disease Control and Preven-
tion.(13,27) Interestingly, 8 of the 9 cases in DILIN
arose in older men with a mean age of 69, but none of
the patients had overt risk factors for acquiring HEV
infection such as eating undercooked pork or wild
game.(13) The initial cause of ALF in our 3 patients
included DILI attributed to atorvastatin (case 1),
APAP overdose (case 2), and fulminant HBV (case 3).
The absence of detectable HEV RNA in all 3 of our
ALF cases was unexpected given that previous series of
severe acute HEV genotype 1 infection from India
have demonstrated readily detectable HEV RNA in
60%-80% of patients and 4 of the 9 DILIN patients
had detectable HEV RNA.(4,13) Nonetheless, the liver
histopathology in case 1 was consistent with the pat-
tern of liver damage reported in previous cases of acute
HEV. However, the histological pattern of liver injury
in case 2 was more consistent with APAP-related liver
injury with prominent pericentral necrosis. The detec-
tion of a high level of serum APAP-protein adducts in
this patients case suggest that the patient likely had
unrecognized APAP hepatotoxicity in addition to pos-
sible acute HEV infection. Case 3 was also a complex
individual who had evidence of acute HBV infection
with possible acute HEV as well. In addition, stool
samples and fresh frozen liver tissue were not available
for PCR testing to confirm the presence of replicating
HEV infection at the time of ALF onset in any of our
patients. Furthermore, specially prepared sera for
growth of HEV in tissue culture were also not avail-
able. Testing of convalescent sera was only possible in
case 2, and, interestingly, anti-HEV IgG was no lon-
ger detectable during prolonged follow-up. Of note,
this LT recipient did not develop evidence of chronic
hepatitis or chronic HEV infection, which has been
previously reported in other solid organ transplant
recipients who had detectable HEV RNA pretrans-
plant.(28-30) In addition, more-recent studies from
France have demonstrated that up to 40% of HEV
RNA1 solid organ transplant recipients will spontane-
ously clear HEV RNA within 2 years of transplant.(31)
A large proportion of our cohort was anti-HEV
IgG positive (43.4%; Table 2). This rate is significantly
higher than the seroprevalence of past HEV infection
reported in a large population-based study done using
the same assay (43.4% vs. 21.0%; P < 0.0001).(9) In
the previous study, the seroprevalence of HEV infec-
tion was consistently higher in men compared to
women and increased in both sexes with age, suggest-
ing that immunity to HEV may be acquired over time
by environmental exposure despite the absence of clini-
cal hepatitis. Of note, pigs and wild game are known
reservoirs of HEV genotype 3 infection in the United
States and Germany.(10,32) Consumption of under-
cooked organ meats and pork has been associated with
zoonotic transmission of HEV to humans.(33) Further-
more, all of the cases of acute sporadic hepatitis in
Western patients from the United States, UK, and
France have been attributed to HEV genotype 3 infec-
tion and not HEV genotype 1 or 2 infection.(2) Our
data demonstrated a higher seroprevalence of anti-
HEV IgG in older versus younger ALF patients simi-
lar to population studies. In addition, there were
remarkable geographical similarities of anti-HEV IgG
seroprevalence in our cohort compared to the general
U.S. population, with the highest rates noted in ALF
patients from the Midwest (50%) and the lowest in
those from the Southeast (28%). Last, the proportion
of patients with detectable anti-HEV IgG declined
over time during the study period from 1998 to 2011
(Supporting Figure S1). Other studies have also noted
a decline in the prevalence of anti-HEV IgG-positive
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blood donors and individuals in the general population
using the same assay.(23,36) The reason for the declin-
ing seroprevalance in Western patients over time is
unknown, but a consistent finding.
Given that 20%-30% of healthy blood donors have
detectable anti-HEV IgG, it is possible that the high
seroprevalence of anti-HEV IgG in our cohort may be
attributed to passive transfer of antibody from blood
products given before their study enrollment. Given
that fresh frozen plasma acquired from multiple donors
is frequently required for ALF patients undergoing
procedures and as many as 20% of healthy blood
donors have detectable anti-HEV IgG, some of the
ALF patients may have simply acquired detectable
anti-HEV through transfusion.(34)
In 2004, we tested sera of 126 ALF indeterminate
patients for occult HEV infection using a PCR assay
for HEV RNA and anti-HEV IgM and IgG levels
using an ELISA assay based upon two recombinant
antigens derived from a Burmese isolate of HEV.(17)
Although 11 patient samples demonstrated some reac-
tivity to one or more HEV peptides, none of them
demonstrated any detectable HEV RNA and the pat-
tern of IgM results was inconsistent, suggestive of
false-positive test results. Overall, the current set of
data appears to be more accurate and reliable because
of the high level of reproducibility achieved with this
assay in multiple laboratories.(34,35) In addition, there
was a high degree of concordance of our data with data
generated by the Wantai assay that was used in a lim-
ited number of these cases as well. Recent studies have
demonstrated that an alternative ELISA assay may
have superior sensitivity and specificity compared to
the assay used in our study, but additional studies are
needed.(23,36) Limitations of our study include the lack
of testing fresh frozen tissue or stool samples at the
time of ALF presentation for HEV RNA, which is
known to be more sensitive than serum HEV-RNA
testing. In addition, stored frozen sera were used for
this study, which could have led to analyte degradation
during prolonged storage. However, previous studies
done by the authors have demonstrated durable anti-
HEV IgM and anti-HEV IgG levels with repeated
freeze thaw cycles and prolonged cold storage.(20)
In summary, these data demonstrate that previously
unsuspected acute HEV infection is an exceedingly
uncommon cause of ALF in the United States. Further-
more, unsuspected acute HEV infection was not impli-
cated in any of the indeterminate, pregnancy-, nor
autoimmune-related ALF patients, and classic HEV-
RNA-positive ALF was not recognized in any of our
patients. The lack of detectable HEV RNA in all 3 of
the anti-HEV IgM-positive cases makes it difficult to
know whether the acute HEV infection was the primary
or secondary reason for ALF and whether it was impor-
tant at all or simply represented a false-positive IgM test
in a patient with perhaps recently past inapparent infec-
tion. Case 1 had evidence of underlying steatohepatitis
and was confounded by statin use. Case 2 likely had a
component of liver injury from APAP hepatotoxicity
and case 3 had presumed concomitant acute HBV
infection. In addition, the absence of stool and fresh
liver tissues did not allow us to confirm the presence of
replicating HEV genotype 3 infection. Finally, no iden-
tifiable risk factor, such as travel to an endemic area or
ingestion of undercooked pork or organ meats, could be
identified in these 3 case patients. Despite these limita-
tions, we feel that it is more likely than not that acute
HEV infection played some role in all 3 cases. The high
seroprevalence of anti-HEV IgG in our study mirrors
the age, sex, and geographical distribution of past HEV
infection reported in population-based studies of HEV
in the United States using the same assay. Subjects with
anti-HEV IgG had a significantly lower 3-week survival
and a greater need for emergency LT compared to the
anti-HEV IgG-negative patients, which may be attrib-
uted to their higher rate of non-APAP-related ALF as
well as their increased age.(14,18)
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Members and institutions participating in the
Acute Liver Failure Study Group 1998-2011 are as
follows: W.M. Lee, M.D. (Principal Investigator),
George A. Ostapowicz, M.D., Frank V. Schiødt,
M.D., Julie Polson, M.D., University of Texas
Southwestern, Dallas, TX; Anne M. Larson, M.D.,
Iris Liou, M.D., University of Washington, Seattle,
WA; Timothy Davern, M.D., University of Califor-
nia, San Francisco, CA (current address: California
Pacific Medical Center, San Francisco, CA), Oren
Fix, M.D., University of California, San Francisco;
Michael Schilsky, M.D., Mount Sinai School of
Medicine, New York, NY (current address: Yale
University, New Haven, CT); Timothy McCashland,
M.D., University of Nebraska, Omaha, NE; J. Eileen
Hay, M.B.B.S., Mayo Clinic, Rochester, MN;
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Natalie Murray, M.D., Baylor University Medical
Center, Dallas, TX; A. Obaid S. Shaikh, M.D., Uni-
versity of Pittsburgh, Pittsburgh, PA; Andres Blei,
M.D., Northwestern University, Chicago, IL
(deceased), Daniel Ganger, M.D., Northwestern
University, Chicago, IL; Atif Zaman, M.D., Univer-
sity of Oregon, Portland, OR; Steven H.B. Han,
M.D., University of California, Los Angeles, CA;
Robert Fontana, M.D., University of Michigan, Ann
Arbor, MI; Brendan McGuire, M.D., University of
Alabama, Birmingham, AL; Raymond T. Chung,
M.D., Massachusetts General Hospital, Boston,
MA; Alastair Smith, M.B., Ch.B., Duke University
Medical Center, Durham, NC; Robert Brown,
M.D., Cornell/Columbia University, New York, NY;
Jeffrey Crippin, M.D., Washington University, St.
Louis, MO; Edwyn Harrison, Mayo Clinic, Scotts-
dale, AZ; Adrian Reuben, M.B.B.S., Medical Uni-
versity of South Carolina, Charleston, SC; Santiago
Munoz, M.D., Albert Einstein Medical Center,
Philadelphia, PA; Rajender Reddy, M.D., University
of Pennsylvania, Philadelphia, PA; R. Todd Stravitz,
M.D., Virginia Commonwealth University, Rich-
mond, VA; Lorenzo Rossaro, M.D., University of
California Davis, Sacramento, CA; Raj Satyanar-
ayana, M.D., Mayo Clinic, Jacksonville, FL; and
Tarek Hassanein, M.D., University of California,
San Diego, CA. The University of Texas Southwest-
ern Administrative Group included Grace Samuel,
Ezmina Lalani, Carla Pezzia, and Corron Sanders,
Ph.D., and Nahid Attar; the Statistics and Data
Management Group included Joan S. Reisch, Ph.D.,
Linda S. Hynan, Ph.D., Janet P. Smith, Joe W.
Webster, and Mechelle Murray; and the Medical
University of South Carolina Data Coordination
Unit included Valerie Durkalski, Ph.D., Wenle
Zhao, Ph.D., Catherine Dillon, and Tomoko
Goddard.
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